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Glial cells, and in particular astrocytes, are crucial to maintain neuronal microenvironment
by regulating energy metabolism, neurotransmitter uptake, gliotransmission, and
synaptic development. Moreover, a typical feature of astrocytes is their high expression
level of connexins, a family of membrane proteins that form gap junction channels
allowing intercellular exchanges and hemichannels that provide release and uptake
pathways for neuroactive molecules. Interestingly, several studies have revealed
unexpected changes in astrocytes from depressive patients and rodent models of
depressive-like behavior. Moreover, changes in the expression level of the astroglial
connexin 43 (Cx43) have been reported in a depressive context. On the other hand,
antidepressive drugs have also been shown to impact the expression of this connexin
in astrocytes. However, so far there is little information concerning the functional
consequence of these changes, i.e., the status of gap junctional communication and
hemichannel activity in astrocytes exposed to antidepressants. In the present work
we focused our attention on the action of seven antidepressants from four different
therapeutic classes and tested their effects on Cx43 expression and on the two
connexin-based channels functions studied in cultured astrocytes. We here report that
when used at non-toxic and clinically relevant concentrations they have no effects on
Cx43 expression but differential effects on Cx43 gap junction channels. Moreover, all
tested antidepressants inhibit Cx43 hemichannel with different efficiency depending on
their therapeutic classe. By studying the impact of antidepressants on the functional
status of astroglial connexin channels, contributing to dynamic neuroglial interactions,
our observations should help to better understand the mechanism by which these drugs
provide their effect in the brain.
Keywords: gap Junctions, hemichannels, glial cells, depression, inflammation
INTRODUCTION
During the two last decades, a major step in the understanding of brain functions and dysfunctions
has been to consider that not only neurons are at the center of these processes but that also their
glial environment is actively involved. This statement is particularly true for astrocytes, a major
glial cell population that establishes tight morphological and functional interactions with neurons
(Halassa and Haydon, 2010; Verkhratsky et al., 2012) leading to the concept of the “tripartite
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synapse” (see Araque et al., 1999; Pérez-Alvarez and Araque,
2013). In brain pathologies and mental illness this partnership
is impaired, contributing to severe neuronal defects and even
in certain cases leading to neuronal death (Giaume et al., 2007;
Bennett et al., 2012; Parpura et al., 2012). Such alterations
in neuroglial interaction start to be investigated in order to
identify and develop alternative therapeutic approaches that
target astrocytes instead of solely neurons (Colangelo et al.,
2014; Lundgaard et al., 2014; Vardjan et al., 2015). Following
this strategy, the objective is to act on a speciﬁc astroglial
molecular constituent known to regulate neuronal activity and/or
survival. Based on these requirements astroglial connexins
(Cxs), a family of membrane proteins, may be considered
as a good candidate. Indeed, Cxs are highly expressed in
astrocytes compared to all other brain cell populations (see
Ransom and Giaume, 2013), including neurons, and they
have been reported to interplay with synaptic activity and
plasticity (Pannasch et al., 2011), animal behavior (Stehberg
et al., 2012), and neuronal survival (Froger et al., 2010; Freitas-
Andrade and Naus, 2015). Besides, the expression and function
of astroglial Cxs are aﬀected in neurodegenerative diseases
(Kawasaki et al., 2009; Koulakoﬀ et al., 2012; Takeuchi and
Suzumura, 2014), ischemia and stroke (Orellana et al., 2014),
epilepsy (Mylvaganam et al., 2014), demyelinating diseases
(Cotrina and Nedergaard, 2012) and cancer (Naus and Laird,
2010). Much less is known about the status, i.e., expression
and function, of Cxs in astrocytes in non-neurodegenerative
mood disorders such as depression, while those pathologies
are associated to a reduction in the number of astrocytes
and a decrease in GFAP immunoreactivity (see Rajkowska and
Stockmeier, 2013).
Connexins are the molecular constituents of gap junctions
that are membrane specializations consisting of dense aggregates
of large pore channels formed by two paired hexamers of Cxs.
These gap junction channels extend from one cell into an
adjacent cell andmediate a unique direct cytoplasm-to-cytoplasm
communication. These channels are poorly selective for ions
and for small molecular weight signaling molecules, thus they
allow extensive ionic and biochemical exchanges between cells
(Harris, 2007). In astrocytes, gap junction channels provide
the basis for ionic homeostasis, particularly for potassium
buﬀering and intercellular calcium signaling. They are also
involved in biochemical and metabolic coupling (see Ransom
and Giaume, 2013). Under certain conditions Cxs can also
operate as half of a gap junction channel, named “hemichannel,”
representing another functional state that provides a pathway
suitable for autocrine as well as paracrine interactions in the
brain. In astrocytes, connexin hemichannels are permeable
to ions and are involved in the release of gliotransmitters
such as ATP and glutamate (Ye et al., 2003; Kang et al.,
2008; Abudara et al., 2015), the uptake of glucose (Retamal
et al., 2007) and the eﬄux of glutathione (Rana and Dringen,
2007; Ye et al., 2015). In astrocytes two major Cxs have
been identiﬁed, Cx43 and Cx30, which are not expressed
in other brain cell types and are characterized by diﬀerent
developmental and regional patterns of expression (Nagy et al.,
2004). Both Cxs contribute to gap junctional communication
but so far only hemichannels made by Cx43 have been
reported to be functional in astrocytes (see Giaume et al.,
2013).
The information concerning astroglial Cxs and depression
is based on two kinds of observations available from the
literature. Firstly, those that report changes in the expression
of astroglial Cxs from depressive patients, persons having
committed suicide or from animal models of depression.
Indeed, a Canadian study of postmortem generated microarray
data suicide completers indicated that the expression level
of Cx43 and Cx30 is reduced in dorsal lateral prefrontal
cortex (Ernst et al., 2011) and in the locus coeruleus (Bernard
et al., 2011). In addition, a recent study has reported that
the expression of Cx43 is reduced in postmortem brains from
patients suﬀering from major depressive disorder or comorbid
depression relative to healthy subjects (Miguel-Hidalgo et al.,
2014). Also, Sun et al. (2012) have reported a decrease in
diﬀusion of gap junction channel-permeable dye and expression
of Cx43 in the prefrontal cortex in rats subjected to chronic
unpredictable stress. Secondly, on the other side treatment
with antidepressants also results in changes in the expression
level of Cx43 in astrocytes as indicated in Table 1. Five
antidepressants, from three diﬀerent therapeutic classes, have
been tested in cellular and animal models; results indicate that
24–48 h treatment induces an increase in Cx43 expression at
mRNA and/or protein levels. This is particularly the case for
ﬂuoxetine that has been tested in several models (Fatemi et al.,
2008; Mostafavi et al., 2008; Sun et al., 2012). However, there
is little information about the eﬀect of these drugs on the
functional status of gap junctional communication and none
about hemichannel activity. So far based on this literature it
is tempting to deduce and summarize that depressive brains
show a down-regulation of Cx43 while antidepressant treatments
favor its up-regulation (see Rajkowska and Stockmeier, 2013).
Nevertheless, an important clue concerning Cxs is to identify
the functional consequences of these treatments on Cx43-
based channels since changes in level of expression can have
unpredictable consequences on their function. In order to
address this question we have carried out a systematic test
of seven antidepressants on gap junctional communication
and hemichannel activity in primary cultures of astrocytes,
known to express only Cx43 (Dermietzel et al., 1991; Giaume
et al., 1991; Koulakoﬀ et al., 2008). The present study
indicates that when used at a non-toxic and clinically relevant
concentration they have diﬀerential eﬀects on both channel
functions leading to a more complicated global view of their
action on intercellular communication mediated by Cx43 in
astrocytes.
MATERIALS AND METHODS
All experiments were performed according to the European
Community Council Directives of 2010/63/UE and all eﬀorts
were made to minimize the number of animals. This study was
carried out in accordance with the recommendations of the Ethic
Committee 59, Paris, France and received the approval of the
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TABLE 1 | Summary table of the effects of antidepressants on Cx43 expression and gap junctional function in astrocytes.
Antidepressant Class Effect on Cx43 expression Effect on
Cx43 function
Model Treatment (dose and time) Reference
Amitriptyline TCA Increase (mRNA, protein) Increase
(gap junction)
Primary cultures rat
cortical astrocytes
25 μM, 48 h Morioka et al., 2014
Clomipramine TCA Increase (protein) NT Primary culture rat
cortical astrocytes
10 μM, 48 h Morioka et al., 2014
Fluoxetine SSRI Increase (protein) NT Rat in vivo
Prefrontal cortex
20 mg/kg i.p. for 21 days Fatemi et al., 2008
Fluoxetine SSRI Increase (mRNA, protein) NT Human astrocytoma
cell line
10, 20 μg/ml 24 h Mostafavi et al., 2008
Fluoxetine SSRI Increase (protein) No effect
(gap junction)
Rat in vivo
Prefrontal cortex
10 mg/kg 21 days Sun et al., 2012
Duloxetine SNRI Increase (mRNA, protein) No effect
(gap junction)
Rat in vivo
Prefrontal cortex
10 mg/kg 21 days Sun et al., 2012
Fluvoxamine SSRI Increase (protein) NT Primary cultures rat
cortical astrocytes
25 μM 48 h Morioka et al., 2014
Scientiﬁc Committee of the animal facilities of the Collège de
France.
Cortical Astrocyte Cultures
Primary astrocyte cultures were prepared from the cortex
of newborn (1–2 days) OF1 mice as previously described
(Meme et al., 2006). For western blot and scrape-loading
dye-transfer experiments, cells were seeded on polyornithine-
coated 35-mm-diameter dishes (Nunc, Roskilde, Denmark) at
a density of 5 × 105cells/mL. For hemichannel experiments
cells were seeded (2 × 105 cells per well) on glass coverslips
(Gassalem, Limeil-Brévannes, France) placed inside 24-round-
well plate; area 1.9 cm2/well; (NunClon, Thermoscientiﬁc,
Atlanta, GA, USA). Cellular medium, DMEM (Sigma–Aldrich,
St-Louis MO, USA), supplemented with penicillin (5 U/ml),
streptomycin (5 μg/ml; Invitrogen, Carlsbad, CA, USA),
fungizone amphotericin B (500 ng/mL; Gibco, Life Technologies,
Carlsbad, CA, USA), and 10% FCS (Hyclone, Logan, UT,
USA), was changed twice a week. When cells reached
conﬂuence, around 10 days in vitro (DIV), they were harvested
with trypsin-EDTA (Invitrogen). The medium was changed
twice a week until the experiments were carried out. In
order to characterize the proportion of microglia in primary
culture of astrocytes, the two cell types were identiﬁed by
immunostaining with Isolectine B4 and GFAP antibodies,
respectively.
Products and Cell Treatments
Astrocyte cultures were treated for 24 h with lipopolysaccharide
(LPS, 1 μg/ml) and/or the following antidepressants: ﬂuoxetine,
duloxetine, paroxetine, reboxetine, amitriptyline, imipramine,
venlafaxine (5, 10, or 20 μM, Sigma–Aldrich, Saint-Louis, MO,
USA). Carbenoxolone (50 μM, Sigma–Aldrich) was used as
positive inhibitor control for gap junction channels. Drugs were
prepared either in H20 or DMSO. Control cells received no
treatment and were previously studied with vehicle (H20 or
DMSO) which induced no changes in comparison with untreated
cells.
Determination of Gap Junctional
Communication
Experiments were performed by using the scrape-loading dye-
transfer technique, as previously described (Meme et al., 2006).
Brieﬂy, cells were incubated at room temperature for 10 min in
HEPES buﬀered salt solution containing (in mM): NaCl, 140;
KCl, 5.4; CaCl2, 1.8; MgCl2, 1; glucose, 10; HEPES, 5 at pH
7.4. Cells were then washed with a calcium-free HEPES solution
for 1 min and the scrape loading and dye transfer assay (see
Giaume et al., 2012) was carried out in the same calcium-free
solution containing Lucifer yellow CH (427 Da, 1 mg/ml). One
minute after scraping procedure, cells were washed with the
HEPES solution and then Lucifer yellow loaded in the cells was
allowed to diﬀuse through gap junction channels for 8 min.
Photomicrographs were taken and data were quantiﬁed using
NIS Nikon software. In all experiments, the ﬂuorescence area of
the ﬁrst row of cells initially loaded, as measured in the presence
of the gap junction channel inhibitor carbenoxolone (50 μM,
24 h), was subtracted from the total ﬂuorescence area.
Ethidium Bromide Uptake Experiments
in Cortical Astrocyte Cultures
Following 10 min exposure to 5 μM ethydium bromide (EtBr),
cells were washed with HEPES buﬀered salt solution containing
(in mM): NaCl, 140; KCl, 5.4; CaCl2, 1.8; MgCl2, 1; glucose,
10; HEPES, 5 at pH 7.4. After 10 min in ﬁxing solution (4%
paraformaldehyde in 0.12 M buﬀer phosphate) and rinsing
with phosphate buﬀered saline (PBS), cells were mounted
in Fluoromount-G mounting medium (Orellana et al., 2011).
Images of astrocyte cultures were taken with a 40× objective
using a confocal laser-scanning microscope (Leica TBCS SP5).
Stacks of consecutive confocal images for 10 μm at 0.49 μm
intervals were acquired with an argon ion laser at 488 nm.
Confocal images of EthBr uptake were analyzed with Image
J software. The EtBr ﬂuorescence intensity in the nuclei of
astrocytes in each image was measured and the average of six
images of diﬀerent areas in the same culture was calculated the
ﬁnal measurement of dye uptake in that culture.
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Western Blot
After 24 h of treatment, cultures were rinsed with PBS 1X and
added 75 μL of a solution containing protease and phosphatase
inhibitors (orthovanadate 1 mM; α-glycerophosphate 10 mM),
and complete miniprotease inhibitor (Roche Diagnostics,
Meylan, France). Cells were then harvested by scraping with
a rubber policeman and pelleted cells were added 20 μL of
5X Laemmli sample buﬀer. Samples were boiled for 5 min,
placed on ice, and lysed by sonication (Ultrasonic cell disrupter,
Microson, Bruxelles, Belgium). Then, samples were stored at
−20◦C. Proteins were measured with the Bio-Rad protein assay
(Bio-Rad laboratories, Richmond, CA, USA). For each cell lysate
sample, 20 μg of proteins were separated on Bis-Tris 4–12%
NuPAGE gels and electro-transferred to nitrocellulose sheets
as previously described (Orellana et al., 2011). Non-speciﬁc
protein binding was blocked by incubation of nitrocellulose
sheets in tris-buﬀered saline (TBS) – Tween – milk solution
(500 mL TBS 1X; 500 μL Tween 20X; non-fat powder milk
25 g) for 1 h. Blots were then incubated overnight with primary
antibody mouse Cx43 1:500 (Transduction Laboratories, Le
Pont de Claix, France) at 4◦C, followed by 4 × 15 min PBS
washes. Blots were incubated with goat anti-mouse antibody
1:2500 conjugated to horseradish peroxidase (Tébu, Le Perray-
En-Yveline, France). Immunoreactivity was detected by ECL
detection using the SuperSignal kit (Pierce, Rockford, IL, USA)
according to instructions. Blots were then reprobed with mouse
monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase
peroxidase (Sigma–Aldrich, 1:10,000) to check the protein load.
Chemiluminescence imaging was performed on a LAS4000
(Fujiﬁlm, Stamford, CT, USA). Semiquantitative densitometric
analysis was performed with ImageJ software after scanning the
bands.
Statistical Analysis
For each data group, results are expressed as mean ± SEM and
n refers to the number of independent experiments. Kruskal–
Wallis test and one-way ANOVA, followed, respectively, by Dunn
and Bonferroni post tests, were used as well as unpaired t-test.
Diﬀerences are considered signiﬁcant at ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001 versus control, +P < 0.05, ++P < 0.01, and
+++P < 0.001 vs. LPS. GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA, USA) was used for calculations.
RESULTS
The doses of the antidepressants were chosen in accordance with
literature addressing the neuropharmacokinetics of the tested
molecules of interest. Accordingly, cultured cortical astrocytes
were treated with concentrations identical to those reported
for brains of human or rodent after treatment with clinically
relevant doses from in vivo studies: for ﬂuoxetine, 20 μM in
human brain is achieved at 20 mg/day (see Henry et al., 2005);
for venlafaxine, 10 μM in mice brain is reached at 20 mg/kg
(Karlsson et al., 2011); for duloxetine, 4.2 mg/kg in rat leads to
10 μM in brain (Kielbasa and Stratford, 2012). For the other
molecules (amitriptyline, imipramine, paroxetine, reboxetine)
the doses were selected below cell toxicity that was identiﬁed by
microscopic examination of astrocyte cultures treated for 24 h,
related to changed cell morphology and entry of Lucifer yellow
into damaged cells. More precisely the lack of toxicity of the
selected doses was routinely validated by the absence of Lucifer
yellow unspeciﬁc uptake in area far from the scrape lines in
scrape-loading dye-transfer experiments (see Figure 1A). Based
on these criterions all molecules were tested at concentrations
between 5 and 20 μM (24 h) for toxicity; we observed that
ﬂuoxetine at 20 μM, paroxetine 10 μM, and duloxetine 20 μM
were toxic at these indicated doses, consequently these molecules
were tested at lower doses.
FIGURE 1 | Modulation of astrocyte Cx43 gap junctional
communication after 24-h treatment by seven antidepressants in mice
cortical astrocyte cultures. Amitriptyline (AMIT), imipramine (IMI), fluoxetine
(FLUOX), paroxetine (PAROX), reboxetine (REBOX), duloxetine (DULOX), and
venlafaxine (VENLA) were added from 5 to 20 μM in cellular medium during
24 h, gap junctional communication was evaluated by the scrape loading dye
transfer method. (A) Pictures of control, paroxetine 5 μM, venlafaxine 5 μM,
and amitriptyline 20 μM, illustrate the Lucifer yellow spreading through
astrocyte gap junctions for these different treatments. (B) Summary diagram
of junctional communication in vehicle-treated cells (control group) and after
antidepressant treatment. Note that the values are normalized to
carbenoxolone (50 μM, 24 h). Data are the means ± SEM n = 3–7 per group,
∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 vs. control, Kruskal–Wallis test and one-way
ANOVA followed, respectively, by Dunn and Bonferroni post test. Scale bar
20 μM.
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The ﬁrst question addressed during this screening with
antidepressants was their eﬀect on the level of Cx43 expression
investigated by western blotting. As indicated in Table 2, the
seven tested antidepressants did not signiﬁcantly modify the
level of expression of Cx43 studied in cultured cortical mouse
astrocytes (n = 3–6 per group, p> 0.05 One way ANOVA, Dunn
post test).
The eﬀect of the selected antidepressants on gap junctional
communication was then tested by using the scrape-loading dye
transfer technique (see Giaume et al., 2012). In control condition
after 10 min the Lucifer yellow diﬀuses widely perpendicular
to the scrape line that indicates a high level of gap junctional
communication (Figure 1A, control). As illustrated in Figure 1B,
three diﬀerent eﬀects were observed. Three antidepressants,
amitriptyline (20 μM; Figure 1A), ﬂuoxetine (10 μM), and
venlafaxine (5 μM; Figure 1A) reduced intercellular dye spread
by 57% (n = 6), 25% (n = 6), and 15% (n = 6), respectively. In
contrast, paroxetine (5 μM; Figure 1A) increased dye coupling
by 19% (n = 7). Finally, imipramine (20 μM, n = 3), reboxetine
(10 μM, n = 6) and duloxetine (5 μM, n = 9) had no statistically
signiﬁcant action on the level of intercellular communication
between astrocytes, neither at these doses nor at higher non-toxic
doses.
In normal condition, astrocytes in culture as well as in
acute slices are characterized by a high level of gap junctional
communication and low hemichannel activity (Bennett et al.,
2003; Retamal et al., 2007; but see Chever et al., 2014). However,
in most pathological situations involving brain inﬂammation, a
reactive gliosis is associated with elevated hemichannel activity
in astrocytes (see Bennett et al., 2012; Giaume et al., 2013).
Such low hemichannel activity was also observed in our culture
condition (Figure 2A). Therefore, to induce hemichannel activity
we treated our cortical primary cultures, in which 11% (n = 9) of
isolectin B4-positive microglia versus GFAP-positive astrocytes
were present, with the endotoxin LPS. As already reported
for in vitro astrocytes (Retamal et al., 2007), we observed
that LPS treatment (1 μg/ml, 24 h) inhibited gap junctional
communication by 64% (n = 6), in such condition we found that
the antidepressants amitriptyline (20 μM, n = 4), imipramine
(20 μM, n = 4), venlafaxine (5 μM, n = 3), and duloxetine
(5 μM, n = 4) did not reverse the inhibition induced by LPS,
when co-treated during 24 h in astrocyte cultures. However,
paroxetine (5 μM, n = 4) and reboxetine (10 μM, n = 3)
reversed LPS-induced uncoupling, in a low but signiﬁcant
manner, respectively, by 17% (n = 4) and 10% (n = 3) whereas
ﬂuoxetine (10 μM) improved it by 10% (n = 4; data not
illustrated). Moreover, we found that LPS treatment (1 μg/ml,
24 h) increased by 104% (n = 7) the uptake of ethidium bromide
(EtBr) in GFAP-positive astrocytes indicating that, as previously
reported (Retamal et al., 2007; Abudara et al., 2015) hemichannels
in cortical astrocytes were activated (Figure 2A). As expected
EtBr uptake was inhibited by 93% (n = 3) in the presence
of carbenoxolone (50 μM; 24 h) indicating that this uptake
is mediated through hemichannel activity (Figure 2B). All the
seven antidepressants tested had a signiﬁcant inhibitor eﬀect
on the LPS-induced EtBr uptake, however, with diﬀerence in
their eﬃciency. Indeed, ﬂuoxetine (10 μM), paroxetine (5 μM),
and duloxetine (5 μM; Figure 2A) had pronounced eﬀect and
inhibited EtBr uptake by 97% (n = 3), 93% (n = 3), and
111% (n= 4), respectively (Figure 2B). Meanwhile, amitriptyline
(20 μM; Figure 2A), imipramine (20 μM), reboxetine (10 μM),
and venlafaxine (5 μM) had milder eﬀect with 45% (n = 6),
28% (n = 3), 52% (n = 3), and 23% (n = 4), respectively
(Figure 2B).
DISCUSSION
The objective of the present study was to investigate the eﬀects of
a panel of antidepressants on the property of the astroglial Cx43, a
membrane protein widely expressed in glial cells that contributes
actively to neuroglial interaction in normal and disease brain (see
Ransom and Giaume, 2013). For this purpose we undertook an
in vitro screening of seven antidepressants from four diﬀerent
classes (TCA, SSRI, NRI, SNRI), all implied in serotonin
and/or noradrenaline reuptake inhibition, to characterize their
action on astroglial Cx43 at diverse levels: protein expression,
gap junctional communication and hemichannel function. We
selected a simple cellular system, primary cultures of mouse
cortical and striatal astrocytes in which only Cx43 is detected
(Dermietzel et al., 1991; Giaume et al., 1991; Koulakoﬀ et al.,
2008). The tested concentrations were determined either based
on the literature, when clinically relevant doses were available,
or by establishing experimentally their threshold of toxicity for
24 h treatment (see Results section). While we did not observe
any signiﬁcant change in Cx43 protein level, we found that
antidepressants had diﬀerential eﬀects on astroglial Cx43-based
gap junctional communication as summarized in Table 2. These
TABLE 2 | Summary table of the effect of seven antidepressants for four different classes: tricyclic (TCA), selective serotonin reuptake inhibitor (SSRI),
noradrenaline reuptake inhibitor (NRI), serotonin noradrenaline reuptake inhibitor (SNRI), on Cx43 expression and channel functions in cultured
astrocytes.
Antidepressant Class Concentration tested (µM) Cx43 expression Effect on gap junctional coupling Effect on hemichannels
Amitriptyline TCA 20 No significant effect Inhibition Mild inhibition
Imipramine TCA 20 No significant effect No effect Mild inhibition
Fluoxetine SSRI 10 No significant effect Inhibition Total inhibition
Paroxetine SSRI 5 No significant effect Increase Total inhibition
Reboxetine NRI 10 No significant effect No effect Mild inhibition
Duloxetine SNRI 5 No significant effect No effect Total inhibition
Venlafaxine SNRI 5 No significant effect Inhibition Mild inhibition
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FIGURE 2 | Regulation of hemichannel activity after 24-h
antidepressant treatments in mice cortical astrocytic cultures. LPS
1 μg/mL was added 24-h before experiment to induce hemichannel opening
and hemichannel activity was evaluated by using the ethidium bromide uptake
assay. (A) Pictures of control, LPS alone, LPS + amitriptyline 20 μM, and
LPS + duloxetine 5 μM uptake experiments. (B) Summary diagram of
hemichannel activity in untreated astrocytes (CTRL) and after treatments with
amitriptyline (AMIT), imipramine (IMI), fluoxetine (FLUOX), paroxetine (PAROX),
reboxetine (REBO), duloxetine (DULOX), and venlafaxine (VENLA) were also
added from 5 to 20 μM in cellular medium during 24 h. Carbenoxolone (CBX,
50 μM, 24 h) was used as a positive control for the inhibition of Cx43
hemichannels. Data are the means ± SEM n = 3–6 per group, ∗∗∗p < 0.001
vs. control, +++p < 0.001 vs. LPS, One-way ANOVA followed by Dunn post
test. Scale bar 20 μM.
results are diﬀerent compared those reported in the few articles
that so far have addressed these properties for some of the
antidepressants used in the present study, i.e., amitriptyline,
ﬂuoxetine, and duloxetine (see Tables 1 and 2). Indeed, Sun
et al. (2012) and Morioka et al. (2014) reported, respectively, an
enhancement in Cx43 mRNA and protein levels in astrocytes
from cultured rat astrocytes treated with amitriptyline and in
the prefrontal cortex of rats chronically treated with duloxetine
(Sun et al., 2012; Morioka et al., 2014). Additionally, two
studies have also shown a rise in Cx43 protein levels in the
prefrontal cortex after in vivo treatment with ﬂuoxetine (Fatemi
et al., 2008; Sun et al., 2012), as well as in human astrocytoma
cultures (Mostafavi et al., 2008). However, no changes in Cx43
gap junctional communication have been found after in vivo
treatments with both ﬂuoxetine and duloxetine in rats (Sun
et al., 2012) whereas this Cx43 function was increased after
amitriptyline treatment in cultured rat astrocytes (Morioka et al.,
2014). In our experiments (see Table 2) only paroxetine (5 mM)
was found to increase gap junctional communication while
duloxetine (5 μM) has a slight, but not statistically signiﬁcant
increasing eﬀect. Imipramine (20 μM) and reboxetine (10 μM)
had no eﬀect and an inhibition was observed with amitriptyline
(20 μM), ﬂuoxetine (10 μM), and venlafaxine (5 μM). These
eﬀects were not speciﬁc to a deﬁned class of antidepressants
and allow for taking a step back regarding results from other
models. Indeed, our study demonstrates that the link between
antidepressants and Cx43-mediated intercellular communication
in astrocyte is likely more complex than the literature consensual
interpretation concerning an increase of Cx43 expression and
function, and that opposed eﬀects are observed within a same
therapeutic class. However, when pointing out the diﬀerences
between our results and the current literature, several parameters
must be taken into account. First, the models of study diﬀered:
we used cultured mouse astrocytes, while Sun et al. (2012) and
Fatemi et al. (2008) worked in vivo on rats, and others used
cell culture models from various species and cellular types in
culture (human astrocytoma and rat astrocytes). Second, dosage,
time, and chronicity of the treatments also diﬀer. Indeed, our
in vitro tested concentrations were non-toxic and similar to what
is found in the brain in pharmacokinetics studies addressing
clinically relevant doses for these molecules, and ranged from 1
to 100 μM in the literature. In literature, in vitro treatments were
administered for several minutes to 48 h (see Table 1). We treated
for 24 h, as for example preliminary trials of 48-h treatments
with amitriptyline (20 μM) induced cell toxicity. In addition, in
the studies that were performed using in vivo models, animals
received chronic treatment (see Table 1) that certainly involved
more integrated and complex mechanisms. Taken as a whole
these information complete and extend the knowledge about
the eﬀect of antidepressants on gap junctional communication
in astrocytes. Finally, as no changes in Cx43 expression were
detected after treatment with antidepressant, we suggested that
they act at the post-translational level.
Up-to-now there was no indication about the eﬀect of
antidepressants on the other channel function of Cx43 in
astrocytes, i.e., the hemichannel activity. This lack of information
can be attributed to the fact that for astrocytes this activity
has been established much latter than the gap junction channel
function and that hemichannels are weakly opened in normal
conditions hence requiring a pathological context to be activated
(see Bennett et al., 2003; Giaume et al., 2013). We conﬁrmed
this feature on untreated primary cortical cultures as the Cx
channel inhibitor carbenoxolone had no signiﬁcant no eﬀect
(data not shown) on the uptake of EtBr (see Giaume et al., 2012).
However, we took advantage that our LPS-stimulated cultures
contained a non-negligible proportion of microglial cells (11%),
a situation already identiﬁed to activated Cx43 hemichannels and
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to reduce gap junctional communication in astrocytes (Retamal
et al., 2007). Indeed, we previously showed that when LPS-
stimulated microglia are co-cultured with astrocytes two pro-
inﬂammatory cytokines are released, i.e., TNF-α and IL-1β,
activating Cx43 hemichannel activity in astrocytes (Retamal et al.,
2007; Abudara et al., 2015). Interestingly, LPS has been reported
to cause time-dependent behavioral alterations with sickness
behavior (Huang et al., 2008) and a depressive-like behavior
observed 24 h after LPS challenge (Painsipp et al., 2011; Custódio
et al., 2013); and it is noteworthy that this eﬀect is reversed
by ﬂuoxetine (Yirmiya et al., 2001), imipramine (Tomaz et al.,
2014), paroxetine and duloxetine (Ohgi et al., 2013). Besides, the
level of TNF-α and IL-1β, are increased after LPS treatments in
animal model, similarly to the increase observed in subjects with
major depression disease (Seidel et al., 1995; Sluzewska et al.,
1996; Dowlati et al., 2010; Hannestad et al., 2011). On this basis
LPS has been proposed as an inducer of depressive-like context
(Mello et al., 2013; Ohgi et al., 2013) conﬁrming the interest
of LPS in the evaluation of antidepressant mechanisms. Using
the EtBr uptake assay we found that all tested antidepressants
had an inhibitory eﬀect on LPS-induced astroglial hemichannel
activity. The eﬀect on Cx43-based hemichannel function was
correlated when considering the class of the antidepressants, the
SSRIs (ﬂuoxetine, paroxetine) induced a strong inhibition while
the TCAs (amitriptyline, imipramine) and NRI (reboxetine) had
mild eﬀect, the treatment with SNRI (duloxetine, venlafaxine)
resulting in mixed inhibition eﬃciency. Interestingly, several of
these antidepressants are known to have an inhibitory eﬀect
on the production of pro-inﬂammatory cytokines, in particular
TNF-α and IL-1β, ﬂuoxetine (Chiou et al., 2006; Tai et al.,
2009; Valera et al., 2014), amitriptyline (Obuchowicz et al., 2006;
Tai et al., 2009), paroxetine (Liu et al., 2014), and imipramine
(Lee et al., 2012). Meanwhile venlafaxine, which presents the
lowest inhibitory eﬀect on LPS-induced hemichannel activity
(23%), is the only tested compound that increased the level
of TNF-α (Valera et al., 2014). Taken as a whole these results
could support the idea that antidepressants may control Cx43
hemichannel activity through the production of TNF-a and/or
IL-1β as the result of a reduction of microglial activation.
However, just paroxetine and reboxetine modestly reversed the
inhibition of gap junctional communication induced by LPS,
it could consequently imply that antidepressant eﬀects are not
targeting microglia-released interleukins. It could also suggest
that the antidepressant inhibitory eﬀects on hemichannels are
acting downstream to the microglial step and/or more directly
on the Cx43 hemichannel function. Nevertheless, more work
is needed to decipher the speciﬁc mechanisms involved in the
regulation of astroglial Cx channels by antidepressants, an aim
that is beyond the scope of the present study.
Interestingly, hemichannel activity in astrocytes has been
shown to provide a pathway for glutamate release (Ye et al.,
2003; Abudara et al., 2015). Consequently, the antidepressant
inhibitory action on hemichannel activity could support
the current hypothesis of the action of these drugs on
glutamine/glutamate metabolic cycle (Garakani et al., 2013) and
glutamate transmission (Gorman and Docherty, 2010; Sanacora
and Banasr, 2013) in the pathophysiology of major depression
(Etiévant et al., 2013). Finally, glutamate gliotransmission
mediated by Cx43 hemichannels has been recently reported to
occur in a model of chronic restraint stress (Orellana et al., 2015)
which is admitted as a model inducing depressive-like symptoms
in rodents (Levinstein and Samuels, 2014).
The present study reﬂects the need to re-evaluate the
statement according to which an alternative strategy for
antidepressive treatments is to target astroglial Cx43 and to
increase gap junctional communication. This proposition was
solely based on reports indicating that several antidepressants
favor Cx43 expression levels while a few have investigated
their eﬀect on the functional aspect, i.e., gap junctional
communication. Based on the present results the eﬀect
of antidepressant drugs on astroglial gap junctions appears
more complex than initially thought and suggests that Cx43
hemichannel activity in astrocytes may be part of the mode of
action of these drugs. Finally, our observation, and in particular
those related to hemichannel activity, could beneﬁt to the
understanding of the mode of action of antidepressants in other
pathologies treated by antidepressants such as neuropathic pain
(Dworkin et al., 2010; Finnerup et al., 2015) and for which
the involvement of glial Cx43 hemichannel activity has been
proposed (Chen et al., 2014).
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